Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Stopped early

Conditions studied: Pancreatic Cancer

In brief

The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.

Key facts

Study ID

NCT01326364

Run by

Stanford University

People needed

6

Starts

2010-03-01

Expected to finish

2012-06-01

Last updated by the study team

2016-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• suspected and/or biopsy-proven pancreatic adenocarcinoma, and
• referral to Radiology for pre-treatment baseline pancreatic protocol CT.

You may not qualify if…

• are absolute contraindications to intravenous iodinated contrast or CT scan.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.